C16orf86

Across TCGA pan-cancer cohorts, C16orf86 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated C16orf86 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher C16orf86 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated C16orf86 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, GBM, and CCRCC are the cancer types where C16orf86 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	1.000	0.386	.006	22	view →
GBM	OS	Median	All	0.635	0.942	.011	14	view →
CCRCC	DFS	Median	II,III,IV	0.885	0.615	.006	12	view →
LSCC	OS	Quartile	II,III,IV	0.686	1.000	.032	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

C16orf86–LUAD (DFS)

Open the LUAD breakdown →